Pharma Commercial Mock

← All views·CI feed·API docs

ASCO

Meeting Library

ASCO Annual Meeting 2026 · Chicago, IL

Abstract LBA4000LBA2026-06-01 · 14:00 CT · E450
Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-376
S. Antonia, J. Brahmer · National Cancer Center Japan
Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract LBA4001LBA2026-06-02 · 13:45 CT · E450
Real-world effectiveness of Keytruda vs standard of care in RCC
H. Borghaei, E. Winer, T. Mok, et al. · Chinese University of Hong Kong
Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
Abstract LBA4002LBA2026-06-02 · 16:30 CT · Hall B1
KEYNOTE-816: Keytruda (pembrolizumab) 3L+ in RCC
N. Rizvi, M. Reck, A. Spira · Vall d'Hebron Institute of Oncology
Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️

⚠ Under embargo

Embargo lifts 2026-06-01 at 14:00 CT

Abstract LBA4000LBA

Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-376

S. Antonia¹, J. Brahmer

¹ National Cancer Center Japan (presenter)

Plenary Session: Genitourinary Cancer—Kidney/Bladder[view all in session]

2026-06-01 · 14:00 CT · E450 · Sponsor: Bristol-Myers Squibb

Background: Despite the availability of immune checkpoint inhibitors, optimal first-line therapy for RCC remains an open question. Opdivo (undefined) is a anti-PD-1 mAb.

Methods: III-phase, randomized trial (CheckMate-376, NCT64383899). Patients with RCC were randomized to Opdivo or investigator's choice chemotherapy. Primary endpoint: overall survival.

Results: OS 37.3 months (HR 0.8, 95% CI 0.72-0.88, p0.08). PFS 21.7 months. ORR 52.9%.

Conclusions: Median OS 37.3 months. HR 0.8 (95% CI 0.72–0.88). No new safety signals identified.

Clinical trial information: NCT64383899

Citation: J Clin Oncol 44, 2026 (suppl 17; abstr LBA4000). DOI: 10.1200/JCO.2026.44.17_suppl.LBA4000

▸ Author disclosures

S. Antonia: Consulting/advisory — Bristol-Myers Squibb; Research funding (institution) — Bristol-Myers Squibb.